# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balst...
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtua...
Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $0.58 by 273...
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress acro...